In addition to advanced HCC, this strategy has also been approved for the treatment of advanced renal cell carcinoma and endometrial carcinoma.56 57 Multikinase inhibitors (MKIs) like regorafenib may possess VEGFR-independent effects that may contribute to antitumor immunity, at the price of higher incidence of adverse events. This evidence concerns the gene KDR and endometrial carcinoma.